NUMERO: #20250219

Título: TARGETING MUCOEPIDERMOID CARCINOMA BY THE BROMODOMAIN INHIBITORS ADMINISTRATION

Nome do Apresentador: Luan César da SILVA

Categoria do Trabalho: Painel de pesquisa científica (PPC)

Área Temática: Oncologia

Resumo: Objective: A high-throughput screening of histone modifier drugs showed bromodomain as a novel target able to manage Mucoepidermoid carcinoma (MEC). Here, we evaluated the use of bromodomain inhibitors, BRD-a and BRD-b, as a therapeutic strategy to MEC.
Study design: UM-HMC3a, UM-HMC3b, and UM-HMC5 MEC cells and their cancer stem cells (CSC) were used to establish the effects of BRD-a and BRD-b. Immunofluorescence staining for BRD4 was used to identify the bromodomain levels of tumor cells upon BRD-a and BRD-b administrations. In vitro scratch assays were performed to address cellular migration. The presence of CSC was evaluated by the identification of ALDH enzymatic activity by flow cytometry.
Results: A significant decrease in BDR4 was observed after the BRDa and BRDb administration. BRD-a and BRD-b administration resulted in the halt of cellular migration potential in UM-HMC3a and UM-HMC3b. ALDH levels were reduced in UM-HMC3a and UM-HMC3b for both drugs. Interestingly, no difference was observed in UM-HMC5.
Conclusion: Bromodomain inhibitors could be used to manage MEC through the reduction of cell migration and disruption of their CSC.
Funding: This work was supported by the State of São Paulo Funding Agency (FAPESP) [grant: 2016/05710-4). LCS was supported by FAPESP 2021/13381-9, 2019/06597-5, CNPq 150911/2024-6.

Autor 1:  Luan César da SILVA

E-mail 1:  [email protected]

Autor 2:   Pablo Agustin VARGAS

E-mail 2:  [email protected]

Autor 3 :  Rogerio CASTILHO

E-mail 3:  [email protected]